Genetic and Functional Analyses Point to FAN1 as the Source of Multiple Huntington Disease Modifier Effects.


Journal

American journal of human genetics
ISSN: 1537-6605
Titre abrégé: Am J Hum Genet
Pays: United States
ID NLM: 0370475

Informations de publication

Date de publication:
02 07 2020
Historique:
received: 18 03 2020
accepted: 18 05 2020
pubmed: 27 6 2020
medline: 21 10 2020
entrez: 27 6 2020
Statut: ppublish

Résumé

A recent genome-wide association study of Huntington disease (HD) implicated genes involved in DNA maintenance processes as modifiers of onset, including multiple genome-wide significant signals in a chr15 region containing the DNA repair gene Fanconi-Associated Nuclease 1 (FAN1). Here, we have carried out detailed genetic, molecular, and cellular investigation of the modifiers at this locus. We find that missense changes within or near the DNA-binding domain (p.Arg507His and p.Arg377Trp) reduce FAN1's DNA-binding activity and its capacity to rescue mitomycin C-induced cytotoxicity, accounting for two infrequent onset-hastening modifier signals. We also idenified a third onset-hastening modifier signal whose mechanism of action remains uncertain but does not involve an amino acid change in FAN1. We present additional evidence that a frequent onset-delaying modifier signal does not alter FAN1 coding sequence but is associated with increased FAN1 mRNA expression in the cerebral cortex. Consistent with these findings and other cellular overexpression and/or suppression studies, knockout of FAN1 increased CAG repeat expansion in HD-induced pluripotent stem cells. Together, these studies support the process of somatic CAG repeat expansion as a therapeutic target in HD, and they clearly indicate that multiple genetic variations act by different means through FAN1 to influence HD onset in a manner that is largely additive, except in the rare circumstance that two onset-hastening alleles are present. Thus, an individual's particular combination of FAN1 haplotypes may influence their suitability for HD clinical trials, particularly if the therapeutic agent aims to reduce CAG repeat instability.

Identifiants

pubmed: 32589923
pii: S0002-9297(20)30159-2
doi: 10.1016/j.ajhg.2020.05.012
pmc: PMC7332667
pii:
doi:

Substances chimiques

Multifunctional Enzymes 0
Endodeoxyribonucleases EC 3.1.-
Exodeoxyribonucleases EC 3.1.-
FAN1 protein, human EC 3.1.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

96-110

Subventions

Organisme : Medical Research Council
ID : MR/L010305/1
Pays : United Kingdom
Organisme : NINDS NIH HHS
ID : R01 NS049206
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS091161
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS105709
Pays : United States

Informations de copyright

Copyright © 2020 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Références

Science. 2018 Mar 16;359(6381):1233-1239
pubmed: 29590070
PLoS Genet. 2018 May 11;14(5):e1007274
pubmed: 29750799
Neurobiol Dis. 1994 Dec;1(3):159-66
pubmed: 9173995
Anal Biochem. 2003 Dec 1;323(1):12-8
pubmed: 14622953
Hum Mol Genet. 2019 Feb 15;28(4):650-661
pubmed: 30358836
EBioMedicine. 2019 Oct;48:568-580
pubmed: 31607598
Am J Hum Genet. 2016 Feb 4;98(2):287-98
pubmed: 26849111
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Cell. 2019 Aug 8;178(4):887-900.e14
pubmed: 31398342
Cell. 1993 Mar 26;72(6):971-83
pubmed: 8458085
Ann Neurol. 2016 Jun;79(6):983-90
pubmed: 27044000
BMC Syst Biol. 2010 Mar 19;4:29
pubmed: 20302627
Mol Cell. 2010 Jul 30;39(2):167-9
pubmed: 20670886
Nat Rev Dis Primers. 2015 Apr 23;1:15005
pubmed: 27188817
DNA Repair (Amst). 2018 Sep;69:1-5
pubmed: 29990673
Cell Stem Cell. 2012 Aug 3;11(2):264-78
pubmed: 22748968
Cell. 2015 Jul 30;162(3):516-26
pubmed: 26232222
J Huntingtons Dis. 2015;4(3):279-84
pubmed: 26444025
Cell. 2010 Jul 9;142(1):77-88
pubmed: 20603016
Science. 2014 Jan 3;343(6166):84-87
pubmed: 24336571
Neurology. 2012 Mar 6;78(10):690-5
pubmed: 22323755
Am J Hum Genet. 2018 Sep 6;103(3):349-357
pubmed: 30122542
Nat Genet. 1993 Aug;4(4):398-403
pubmed: 8401589
Breast Cancer Res Treat. 2011 Dec;130(3):1043-9
pubmed: 21858661
Science. 2014 Nov 28;346(6213):1127-30
pubmed: 25430771
Mol Cell. 2010 Jul 9;39(1):36-47
pubmed: 20603073
Cell. 2010 Jul 9;142(1):65-76
pubmed: 20603015
Nat Genet. 1993 Aug;4(4):387-92
pubmed: 8401587
Environ Mol Mutagen. 2010 Jul;51(6):604-24
pubmed: 20658650

Auteurs

Kyung-Hee Kim (KH)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Neurology, Harvard Medical School, Boston, MA 02115, USA.

Eun Pyo Hong (EP)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Neurology, Harvard Medical School, Boston, MA 02115, USA.

Jun Wan Shin (JW)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Neurology, Harvard Medical School, Boston, MA 02115, USA.

Michael J Chao (MJ)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Neurology, Harvard Medical School, Boston, MA 02115, USA.

Jacob Loupe (J)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Neurology, Harvard Medical School, Boston, MA 02115, USA.

Tammy Gillis (T)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.

Jayalakshmi S Mysore (JS)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.

Peter Holmans (P)

Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology, School of Medicine, Cardiff University, Cardiff CF24 4HQ, UK; The GeM-HD consortium, University of Ulm, Ulm 89081, Germany.

Lesley Jones (L)

Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology, School of Medicine, Cardiff University, Cardiff CF24 4HQ, UK; The GeM-HD consortium, University of Ulm, Ulm 89081, Germany.

Michael Orth (M)

The GeM-HD consortium, University of Ulm, Ulm 89081, Germany; Department of Neurology, University of Ulm, Ulm 89081, Germany.

Darren G Monckton (DG)

The GeM-HD consortium, University of Ulm, Ulm 89081, Germany; Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.

Jeffrey D Long (JD)

The GeM-HD consortium, University of Ulm, Ulm 89081, Germany; Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa 52242, USA; Department of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, USA.

Seung Kwak (S)

The GeM-HD consortium, University of Ulm, Ulm 89081, Germany; CHDI Foundation, Princeton, NJ 08540, USA.

Ramee Lee (R)

CHDI Foundation, Princeton, NJ 08540, USA.

James F Gusella (JF)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; The GeM-HD consortium, University of Ulm, Ulm 89081, Germany; Medical and Population Genetics Program, the Broad Institute of M.I.T. and Harvard, Cambridge, MA 02142, USA; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.

Marcy E MacDonald (ME)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Neurology, Harvard Medical School, Boston, MA 02115, USA; The GeM-HD consortium, University of Ulm, Ulm 89081, Germany; Medical and Population Genetics Program, the Broad Institute of M.I.T. and Harvard, Cambridge, MA 02142, USA.

Jong-Min Lee (JM)

Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Neurology, Harvard Medical School, Boston, MA 02115, USA; The GeM-HD consortium, University of Ulm, Ulm 89081, Germany; Medical and Population Genetics Program, the Broad Institute of M.I.T. and Harvard, Cambridge, MA 02142, USA. Electronic address: jlee51@mgh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH